ARX Stock Overview
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARX from our risk checks.
Aroa Biosurgery Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.65 |
| 52 Week High | AU$0.87 |
| 52 Week Low | AU$0.44 |
| Beta | 0.62 |
| 11 Month Change | 12.07% |
| 3 Month Change | 42.86% |
| 1 Year Change | -9.72% |
| 33 Year Change | -43.48% |
| 5 Year Change | n/a |
| Change since IPO | -51.85% |
Recent News & Updates
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aug 22Recent updates
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aug 22Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
Jun 12Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Shareholder Returns
| ARX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 4.0% | -3.6% | 1.5% |
| 1Y | -9.7% | 10.0% | 17.2% |
Return vs Industry: ARX underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: ARX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ARX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ARX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds.
Aroa Biosurgery Limited Fundamentals Summary
| ARX fundamental statistics | |
|---|---|
| Market cap | AU$219.01m |
| Earnings (TTM) | -AU$9.60m |
| Revenue (TTM) | AU$62.38m |
3.6x
P/S Ratio-23.4x
P/E RatioIs ARX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARX income statement (TTM) | |
|---|---|
| Revenue | NZ$69.07m |
| Cost of Revenue | NZ$10.09m |
| Gross Profit | NZ$58.97m |
| Other Expenses | NZ$69.60m |
| Earnings | -NZ$10.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 85.39% |
| Net Profit Margin | -15.39% |
| Debt/Equity Ratio | 0% |
How did ARX perform over the long term?
See historical performance and comparison